Study of three drugs for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs—HRS-2189, adebrelimab, and BP102—for people whose colorectal cancer has spread. The goal is to see if this combination can help shrink tumors or slow the disease. It may be an option if standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to other parts of the body.
- You are physically active and able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You haven't had other cancers in the last 5 years (except for cured skin or cervical cancer).
- You don't have untreated brain or spinal cord spread, or it's been stable for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
This trial studies a combination of three drugs — an immunotherapy (sintilimab), a blood vessel growth blocker (bevacizumab), and a chemotherapy helper (decitabine) — for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer when standard options have failed.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.